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Background: Rapid titration with intravenous morphine (IV-MO) provides fast and efficient pain relief in cancer patients 
with severe-excruciating pain. However, some patients, after an initially favourable response, can develop an hyperexcitated 
state unrelieved or worsened by further dose increments.   
Methods: Eighty-one patients admitted on emergency basis titrated with IV-MO were assessed. 
Results: 12 patients were unsuccessfully titrated with IV-MO. Switching to intravenous methadone (IV-ME) and titrating 
the doses proved to be successfully.  
Conclusion: In escalating opioid doses rapidly a recognition of the development of hyperalgesia should be suspected. 
Increasing doses of opioids may stimulate rather than inhibiting the central nervous system, with complex mechanisms 
already recognized in experimental studies. Switching to IV-ME and titrating the doses could be taken into consideration to 
break this vicious circle before pain conditions worsen irreversibly. 
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 .Introduction
Opioid use has been increasing in the last years. The changing 
pattern in opioid use has resulted in the emergence of 
neurotoxicity as a major adverse effect of the treatment of 
cancer pain (1). Animal studies and clinical reports suggest that 
opioids, intended to abolish pain, can unexpectedly produce 
abnormally heightened pain sensations, which are characterized 
by a lowering of the pain threshold, commonly known as 
hyperalgesia (2,3). Such abnormal sensations could result in an 
exacerbation rather than an attenuation of excitatory behaviours. 
The problem of hyperalgesia, tolerance, and nociception remains 
not clearly understood and quite difficult to interpret in the 
clinical setting of the cancer patients, where multiple factors are 
able to confound the picture (4-6). 
Opioid induced hyperalgesia is a clinical paradox. It is 
possible to hypothesize an iatrogenic syndrome characterized 
initially by a declining analgesia, requiring further opioid 
escalation to maintain the previous level of analgesia, which is 
however fleeting, and then resulting in a worsening of pain and 
whole-body hyperalgesia. Alternately, patients on opioid therapy, 
who present long periods of breakthrough nociception due to 
an inadequate dosage, may require an aggressive treatment with 
increasing opioid doses. Titration with intravenous morphine 
(IV-MO) may provide fast and efficient pain relief, also 
providing information about the amount of opioids necessary 
for a subsequent treatment (7,8). According to the description 
of this iatrogenic syndrome described above, some patients, after 
an initially favourable response, can develop an hyperexcitated 
state worsened by further dose increments (9). 
We here report the rapid establishment of morphine - induced 
hyperalgesia which was reversed by the administration of 
intravenous methadone in a sort of immediate opioid switching 
during rapid titration with intravenous morphine.
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 .Patients and methods
In a period of one year we prospectively analysed patients 
admitted to an acute pain relief and palliative care unit with 
severe pain (intensity >7 on a numerical scale of 0-10) on an 
emergency basis. According to department policy patients 
underwent rapid titration with IV-MO. The protocol has been 
described elsewhere (9). Briefly, boluses of IV-MO were offered 
intensively, in doses of 5-10 mg every five minutes depending on 
the pain intensity and the previous opioid dosage. The effective 
dose of IV-MO is assumed to last approximately four hours 
(according to its duration and half-life) and calculated for the 
next 24 hours as a continuous infusion (the effective dose is 
multiplied for six), eventually supported by the same bolus dose 
for breakthrough pain. 
Patients who did not responded favourably or showing a 
worsening pain despite increasing doses of morphine within 
24 hours, even after an apparent pain relief of short duration, 
were switched to intravenous methadone (IV-ME). Thus, 
the clinical definition of hyperalgesia was the occurrence of 
increasing pain, diffuse in character, in patients who were titrated 
with IV-MO unsuccessfully (pain intensity ≥7, by using a 
numerical scale 0-10), despite an initial but short-lived analgesia, 
reflecting the iatrogenic syndrome describe above.  
Doses of IV-ME were titrated again to relieve pain, at bedside 
and under medical supervision, regardless of prior morphine 
dose: IV-ME titration was stopped when patients reported an 
adequate pain relief. According to the efficacy of the bolus and 
patients' response, a continuous infusion of IV-ME was started 
in doses of approximately three times the dose of the effective 
bolus, as this doses was assumed to provide analgesia for about 
eight hours (while for IV-MO has been considered six times). 
This approach was suggested by initial clinical experience 
with dosing IV-ME after IV-MO. For example, if the patient 
responded positively to a bolus of 10 mg of IV-ME, a continuous 
infusion of 30 mg/day was started. In the subsequent days, 
doses were changed according to the need. After achieving a 
dose stabilization providing adequate analgesia and acceptable 
adverse effects, IV-ME was converted to the oral route (OR-
ME), by using a ratio IV-OR of 0.8-1 (10). For example a patient 
receiving successfully 30 mg/day of IV-ME was converted to 
36 mg of OR-ME. According to patient's preference ME could 
be switched to the initial drug prescribed at admission, using 
conversion ratios previously described (11).
A favourable response was defined as the achievement of 
a stable and acceptable analgesia (pain intensity ≤4, by using 
a numerical scale 0-10). Data were collected and analysed by 
the SPSS Software 14.0 version (SPSS, Inc., Chicago, Ill, US). 
Statistical analysis of quantitative and qualitative data, included 
descriptive statistics, was performed for all the items.
 .Results
Eighty-one patients admitted to the unit on emergency basis 
who were titrated with IV-MO during the period taken into 
consideration were surveyed. 69 patients responded favourably 
to IV- MO titration and were normally converted to oral opioids, 
as per protocol. The median dose of the effective bolus was 
10 mg (range, 4-18 mg). 
Twelve patients were switched and re-titrated with IV-ME, 
because the previous titration with IV-MO failed and produced 
worsening pain rather than pain relief. No traditional adverse 
effects were noticed, except a mild myoclonus in three patients 
(n.1,2,3 in Table 1).
Characteristics of patients, initial bolus doses of IV-MO, 
the effective initial bolus dose IV-ME, and the final doses of 
OR-ME prescribed at time of discharge are presented in Table 
1. The dose ratio between the initial bolus of IV-MO and the 
initial bolus of IV-ME was 2.24. All patients responded to opioid 
switching-titration with IV-ME, achieving stable analgesia (pain 
intensity ≤4, by using a numerical scale 0-10) except one patient 
who required a more complex treatment, including intrathecal 
administration of morphine and bupivacaine. One patient 
preferred transdermal therapy. When excluding the patient who 
required the spinal treatment, patients were discharged at home 
after a mean of 5.5 days (range, 3-9 days) after starting IV-ME.
 .Discussion
In the last years, experimental and clinical studies have pointed out 
the possible hyperalgesic effect of high doses of opioids. Intense 
opioid receptor activation, such as that occurring with a short-lived 
opioid like remifentanyl, induces rapid and extensive tolerance 
which has been shown in humans and perhaps manifesting 
as dramatic hyperalgesia (12,13). This may corresponds to a 
therapeutic paradox where the consequence (increasing pain), is 
treated by favouring its cause (opioid escalation).  
Thus, in escalating opioid doses rapidly a recognition of the 
development of hyperalgesia should be suspected, as higher or 
rapid increases in doses of opioids may stimulate rather than 
inhibiting the central nervous system, with different mechanisms, 
well recognized in experimental studies (2). 
Opioid switching is increasingly used in patients with a poor 
opioid response. The presumed offending drug should be stopped, 
and a rapid opioid substitution should be started (14,15).   
In this circumstances methadone could be an optimal choice 
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for switching, due to the different receptor activity, particularly 
in promoting receptor internalization. Morphine, in comparison 
with other opioids has an high activity-endocytosis ratio, and has 
an enhanced propensity to prolonging signals with prolonged 
drug exposure. Molecular events, such as desensitization 
and endocytosis would reduce this response. It has been 
experimentally demonstrated that endocytosis-promoting 
agonists may reduce the compensatory adaptive cellular changes 
that lead to upregulation of the cAMP pathway (16). 
Of concern, opioids switching often deserves particular 
cautions, particularly when switching to methadone. Regardless 
of the different modalities proposed in literature, all these 
calculations do not take into account the modality of the 
previous opioid escalation from a dynamic point of view, that is 
the short time used to increase the dose of the previous opioid, 
or other causes as driving force for opioid escalation, for example 
the development of opioid-induced hyperalgesia (17). 
An initial bolus of IV-ME, based on the response to IV-MO 
and the previous dosage of opioids, and evaluation of the clinical 
response under a strict surveillance, are clinically the guides 
for the subsequent treatment with an intravenous continuous 
infusion. This was an effective and safe treatment, as dosing is 
determined clinically, regardless of possible calculations, which 
are unreliable in such a clinical situation.   
In a previous experience we reported how difficult can 
be switching patients in the presence of opioid-induced 
hyperalgesia (3). In such circumstances, it is difficult to calculate 
any approximate dose conversion rate. For example, in a case 
reported of many years ago, it has been reported a patient 
receiving parenteral morphine in doses of 21.600 mg/day which 
were converted to about 1% of the calculated equianalgesic 
dose of another opioid (18). In the series presented here, the 
clinical situation was quite complex because switching was 
performed in patients who were unsuccessfully titrated IV-
MO. In unresponsive patients selected for this study, the mean 
dose of IV-MO which were clinically judged as producing 
Table 1. Characteristics of patients, previous treatment, initial IV-MO titration unsuccessful dose, IV-ME titration effective dose and 
opioids prescribed at discharge (mg).
Age Sex
Primary 
tumor
Cause of pain
Previous analgesic 
treatment before
 IV-MO titration
Initial 
IV-MO 
(mg)
Initial 
IV-ME
 (mg)
IV-ME infusion
in the first 
24 hrs
Opioid doses 
at discharge
1 65 M Lung Bone mts OR-MO 200 20 5 15 mg/day OR-ME 60
2 62 M Head-neck
Bone mts 
Neuropathic 
pain post-dissection
OR-OX  60 
Pregabalin 75
20 10 30 mg/day OR-ME 45 
3 58 M Pancreas Locally advanced OR-MO 900 50 20 60 mg/day OR-ME 180
4 50 F Breast Bone mts OR-MO 120 20 7 21 mg/day OR-ME 50
5 55 M Lung Nerve compression OR-OX 20 20 6 18 mg/day OR-ME 36
6 75 F Pancreas Locally advanced OR-OX 60 20 8 24 mg/day OR-ME 36
7 55 M Bladder
Locally advanced 
Bone mts
OR-OX 800 60 20 60 mg/day
OR-ME 30 
IT-MO 12 
IT-BU 15
8 47 M Unknown Bone mts
TD-FE 1.2/day 
(50 µg/h) 
20 10 30 mg/day TD-FE  5.4 
9 62 F Breast Bone mts
TD-FE 1.6/day 
(75 µg/h)
30 12 36 mg/day OR-ME 90
10 76 F Pancreas Locally advanced OR-OX 80 25 15 45 mg/day OR-ME 120
11 64 M Lung Nerve compression OR-MO 150 18 4 12 mg/day OR-ME 35
12 51 F Uterum
Locally advanved 
Nerve compression
OR-OX 30 20 5 15 mg/day OR-ME 24
Mean
7 M
 5 F
Mean OR-MO 
equivalents: 290 (384)
27.5(14.1) 10.6(5.6) 33 mg/day
OR-ME: 
72(50)
OR-MO=oral morphine; OR-OX=oral oxycodone; TD-FE=transdermal fentanyl; OR-ME=oral methadone; IV-MO=intravenous morphine; 
IV-ME=intravenous methadone; IT-MO=intrathecal morphine; IT-BU=intrathecal bupivacaine. Doses are expressed as mg/day. In brackets SD.
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worsening pain was 22.1 mg (range, 18-60 mg). Patients were re-
titrated with IV-ME with a mean dose of 10.1 mg (range 4-20) 
successfully in almost patients. The final mean dose of OR-ME 
before discharge was 67.6 mg. According to the methadone 
IV-OR conversion ratio adopted (10), this means that further 
refinements in methadone doses were needed in the following 
days to produce an adequate analgesia. Moreover the dose ratio 
between the initial bolus of IV-MO and the initial bolus of IV-
ME was 2.24, which is very low in comparison with calculated 
equianalgesic methadone dose. Regardless of the final doses 
and the ratios found in this study, no data exists on direct 
ratios between IV-MO and IV-ME, given that oral availability 
ofmethadone is higher than that of oral morphine, but IV 
availability is similar. In patients who were titrated with IV-MO 
successfully (that is, patients who subsequently maintained 
analgesia after starting infusion) the median effective bolus of 
IV-MO was 10 mg, which is significant lower in comparison 
with unsuccessfully treated patients and similar to that reported 
in a previous study of IV-MO titration (9). Thus, the clinical 
judgement and the clinical impression guided the decision 
to switch to IV-ME, because there are no proofs that further 
increases in doses of IV-MO would produce a further analgesia, 
also considering that the majority of patients did not have other 
adverse effects limiting further dose escalation.
In conclusion, in escalating opioid doses rapidly, particularly IV-
MO, a recognition of the development of hyperalgesia should be 
suspected. Opioid switching to IV-ME after unsuccessful titration 
with IV-MO, likely due to the occurrence of rapid opioid-induced 
hyperalgesia, could be effective in regaining analgesia. However, 
this approach is complex and requires an appropriate setting 
for monitoring patients and providing adequate dose changes 
subsequently according to the clinical response.   
The should be taken with caution, given the paucity of clinical 
data assessing this topic. Unfortunately, the setting of poorly 
controlled pain is often unfit for appropriate controlled studies. 
The problem of hyperalgesia, tolerance, and nociception remains 
not well understood and quite difficult to interpret in the clinical 
setting of the cancer patients, where multiple factors are able 
to confound the picture. An integration of basic knowledge 
and clinical aspects may help assist clinicians to apply specific 
alternative approaches, such as those proposed in this study, in 
daily activity when such difficult conditions occur.
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